A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Iron Sucrose (Venofer) in Iron Deficiency Anemia and Impaired Renal Function, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 3rd largest by enrollment, is one of 6 that started in 2009, is one of 16 in phase 3, and was the 7th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Hawler Medical University
Ages 18–45 · Women only
Zhaojian Niu,MD
Ages 18–75
Children's Hospital of Orange County
Ages 1–18
Liverpool Hope University
Ages 60–85
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 24
First in 2006; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,561 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 57 interventional studies. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 3, and was the 1st registered.
Daiichi Sankyo’s Anemia, Iron-Deficiency studies by the year they started, since 2009.
2 of the studies testing ferric carboxymaltose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
| NCT07772453Zhaojian Niu,MDFerric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, from their registry updates:
Among Daiichi Sankyo’s 13 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to examine the efficacy and safety (cardiovascular) of an investigational intravenous (IV) iron, ferric carboxymaltose (FCM), compared to IV iron sucrose (Venofer) in subjects who have iron deficiency anemia (IDA) and impaired renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
Drug: Ferric Carboxymaltose (FCM)
5 doses of 200 mg for a total cumulative dose of 1000 mg
Drug: Iron Sucrose (Venofer)
2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
5 doses of 200 mg for a total cumulative dose of 1000 mg
Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.
Time frame: Day 56
Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.
The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.
Time frame: Day 120
04-Sept-2009 through 15-Jun-2011; Hospitals and Medical Clinics
| Milestone | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) |
|---|---|---|
| Started | 1290 | 1294 |
| Completed | 1276 | 1285 |
| Not completed | 14 | 9 |
| g/dL | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) |
|---|---|---|
| Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study. | 1.13 ± 1.044 | 0.92 ± 0.917 |
The primary composite safety endpoint was defined as death due to any cause, nonfatal myocardial infarction, nonfatal stroke, unstable angina requiring hospitalization or medical intervention, arrhythmias, protocol-defined hypersensitive events, and protocol-defined hyposensitive events.
| participants | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) |
|---|---|---|
| Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population. | 175 | 156 |
Collected over September 4, 2009 through June 15, 2011. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | — | 202/1,276 (15.8%) | 305/1,276 (23.9%) |
| Iron Sucrose (Venofer) | — | 197/1,285 (15.3%) | 151/1,285 (11.8%) |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 30/1276 | 29/1285 |
| PneumoniaInfections and infestations | 15/1276 | 16/1285 |
| AnemiaBlood and lymphatic system disorders | 14/1276 | 4/1285 |
| Renal failure acuteRenal and urinary disorders | 13/1276 | 11/1285 |
| Acute myocardial infarctionCardiac disorders | 6/1276 | 11/1285 |
| CellulitisInfections and infestations | 10/1276 | 6/1285 |
| Urinary tract infectionInfections and infestations | 10/1276 | 2/1285 |
| Renal failure chronicRenal and urinary disorders | 10/1276 | 10/1285 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 9/1276 | 9/1285 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 9/1276 | 7/1285 |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) |
|---|---|---|
| NauseaGastrointestinal disorders | 172/1276 | 56/1285 |
| HypertensionVascular disorders | 133/1276 | 95/1285 |
14 subjects randomized to receive FCM and 9 subjects randomized to receive Venefor were randomized but discontinued prior to dosing due to subject request or selection criteria/study compliance reasons.
| Age, Categorical(Participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 468 | 500 | 968 |
| >=65 years | 808 | 785 | 1593 |
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) | Total |
|---|---|---|---|
| Mean | 67.5 ± 13.00 | 67.2 ± 13.00 | 67.3 ± 12.99 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) | Total |
|---|---|---|---|
| Female | 810 | 818 | 1628 |
| Male | 466 | 467 | 933 |
| Region of Enrollment(participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (Venofer) | Total |
|---|---|---|---|
| United States | 1276 | 1285 | 2561 |
The record gives a start of Aug 2009, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose